Breast cancer experts share insights on how recently approved indications for 3 ADCs will affect clinical practice.

Gedatolisib plus fulvestrant, with or without palbociclib, has been added to the NCCN Guidelines for select patients with previously treated breast cancer.

Dato-DXd was approved in the European Union as monotherapy for patients with first-line metastatic TNBC who are not candidates for immunotherapy.

The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.

The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.

The CHMP has recommended the approval of sacituzumab govitecan/pembrolizumab for treatment-naive, PD-L1-positive metastatic TNBC in the European Union.

Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.

Camizestrant plus a CDK4/6 inhibitor was approved in the European Union for ER-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.